AHF Calls on Gilead to Set Up $10 Billion Fund for Victims Harmed by its TDF-based Drugs

As pressure continues to mount on Gilead Sciences Inc., one of the largest manufacturers of HIV/AIDS drugs, from withholding improved HIV drugs from the public to increase profits, another foundation is taking the podium. AIDS Healthcare Foundation (AHF) is calling on Gilead to set up a $10 billion compensation fund for victims that took their TDF-based drugs as part of their HIV/AIDS treatment or preventative treatment (PrEP) programs.

Read more

Gilead tries—and fails—to dodge lawsuit claiming it delayed safer HIV meds

After years of allegations directed towards Gilead Sciences regarding their decision to hold back the release of improved next-gen HIV drugs in order to maximize profits from their older generation drugs, a federal judge has finally allowed a key lawsuit to proceed. 140 patients in 31 states have claimed in the lawsuit that Gilead shelved their newly developed tenofovir alafenamide fumarate (TAF) drugs in 2004 to protect the profits from their existing and older franchise drugs tenofovir disoproxil fumarate (TDF). All the while knowing the TAF-based drugs were safer and better for patients.

Read more